Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alx Oncology Holdings 

ALXO
Current price
16.08 USD +1.48 USD (+10.14%)
Last closed 14.49 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 653 481 856 USD
Yield for 12 month +245.06 %
1Y
3Y
5Y
10Y
15Y
ALXO
21.11.2021 - 28.11.2021

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 323 Allerton Avenue, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

20.15 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-836 000 USD

Last Year

-1 466 000 USD

Current Quarter

-207 000 USD

Last Quarter

-209 000 USD

Key Figures ALXO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -169 442 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -38.77 %
PEG Ratio
Return On Equity TTM -70.97 %
Wall Street Target Price 20.15 USD
Revenue TTM
Book Value 3.8 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM 107 000 USD
Earnings Share -3.74 USD
Diluted Eps TTM -3.74 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALXO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALXO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALXO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4254.356
Price Sales TTM 5906.2383
Enterprise Value EBITDA -3.0867
Price Book MRQ 3.4499

Financials ALXO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALXO

For 52 weeks

3.94 USD 17.42 USD
50 Day MA 13.63 USD
Shares Short Prior Month 2 913 735
200 Day MA 9.69 USD
Short Ratio 6.39
Shares Short 3 120 969
Short Percent 12.7 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

411.84 USD Microsoft Corporation -5.76 (-1.38%)
Detailed analytics

ETF funds


M

MDAXEX

208.40 CHF iShares MDAX UCITS ETF (DE) -12.16 (-5.06%)
Detailed analytics

Metals


Gold

2205.6 USD Gold +35.66 (+1.64%)
Detailed analytics